A Study of LY3435151 in Participants With Solid Tumors

NCT04099277 · clinicaltrials.gov ↗

PHASE1

Phase

TERMINATED

Status

2

Enrollment

INDUSTRY

Sponsor class

Stopped Study terminated due to strategic business decision by Eli Lilly and Company.

Conditions

Solid Tumor
Triple-negative Breast Cancer
Gastric Adenocarcinoma
Head and Neck Squamous Cell Carcinoma
Cervical Carcinoma
High Grade Serous Ovarian Carcinoma
Hepatocellular Carcinoma
Undifferentiated Pleomorphic Sarcoma
Leiomyosarcoma

Interventions

DRUG: LY3435151
DRUG: Pembrolizumab

Sponsor

Eli Lilly and Company